604.96 USD
+23.75
4.09%
At close Mar 14, 4:00 PM EDT
After hours
604.96
+0.00
0.00%
1 day
4.09%
5 days
3.91%
1 month
-5.39%
3 months
-4.38%
6 months
12.46%
Year to date
-2.45%
1 year
59.77%
5 years
455.88%
10 years
2,530.26%
 

About: Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Employees: 1,148

0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

126% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 34

107% more call options, than puts

Call options by funds: $375M | Put options by funds: $181M

22% more repeat investments, than reductions

Existing positions increased: 144 | Existing positions reduced: 118

11% more capital invested

Capital invested by funds: $19B [Q3] → $21B (+$2B) [Q4]

11% more funds holding

Funds holding: 352 [Q3] → 389 (+37) [Q4]

2.09% less ownership

Funds ownership: 58.62% [Q3] → 56.52% (-2.09%) [Q4]

10% less funds holding in top 10

Funds holding in top 10: 20 [Q3] → 18 (-2) [Q4]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$680
12%
upside
Avg. target
$752
24%
upside
High target
$1,100
82%
upside

9 analyst ratings

positive
89%
neutral
11%
negative
0%
Guggenheim
Yatin Suneja
30% 1-year accuracy
8 / 27 met price target
82%upside
$1,100
Buy
Maintained
10 Mar 2025
Baird
Joel Beatty
40% 1-year accuracy
17 / 43 met price target
12%upside
$680
Neutral
Maintained
4 Mar 2025
Oppenheimer
Leland Gershell
39% 1-year accuracy
22 / 56 met price target
16%upside
$704
Outperform
Maintained
28 Feb 2025
Wells Fargo
Derek Archila
40% 1-year accuracy
14 / 35 met price target
22%upside
$741
Overweight
Maintained
28 Feb 2025
Citizens Capital Markets
Jason Butler
37% 1-year accuracy
16 / 43 met price target
16%upside
$701
Outperform
Maintained
28 Feb 2025

Financial journalist opinion

Based on 7 articles about ARGX published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in San Diego, CA from April 5-9, 2025.
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Neutral
Seeking Alpha
2 weeks ago
argenx SE (ARGX) Q4 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Alex Thompson - Stifel Derek Archila - Wells Fargo Yaron Werber - TD Cowen Victor Floch - BNP Paribas Rajan Sharma - Goldman Sachs Suzanne van Voorthuizen - Kempen Vikram Purohit - Morgan Stanley Matt Phipps - William Blair Gavin Clark-Gartner - Evercore ISI Samantha Semenkow - Citi Thomas Smith - Leerink Partners Leland Gershell - Oppenheimer Mehdi Goudarzi - Truist Securities Douglas Tsao - H. C. Wainwright Manos Mastorakis - Deutsche Bank Operator Good morning.
argenx SE (ARGX) Q4 2024 Earnings Call Transcript
Positive
Seeking Alpha
2 weeks ago
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
argenx reported Q4 earnings today. Vyvgart's strong Q4 2024 performance, driven by the U.S. CIDP launch, positions it for continued growth with upcoming launches and approvals in Europe, Japan, and the U.S. The sales outlook for 2025 looks strong, and I expect Vyvgart to once again exceed Street expectations. The pipeline catalyst calendar is light for 2025, and several far more important readouts of Vyvgart and one of empasiprubart are expected in 2026.
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
Neutral
GlobeNewsWire
2 weeks ago
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 27, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2024 and provided a fourth quarter business update. "In 2024, we significantly expanded our global patient reach with VYVGART, surpassing 10,000 patients across three indications,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
Neutral
GlobeNewsWire
2 weeks ago
argenx to Present at TD Cowen 45th Annual Healthcare Conference
February 25, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.
argenx to Present at TD Cowen 45th Annual Healthcare Conference
Neutral
GlobeNewsWire
3 weeks ago
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
February 20, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update.
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
Positive
Investors Business Daily
3 weeks ago
Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs
Argenx recently hit an all-time high ahead of fourth-quarter earnings. Shares are in a flat base with a buy point of 678.21.
Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs
Positive
Zacks Investment Research
1 month ago
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Here is how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have performed compared to their sector so far this year.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Positive
Zacks Investment Research
1 month ago
Best Momentum Stocks to Buy for January 20th
ARGX, ALLT and NGD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 20, 2025.
Best Momentum Stocks to Buy for January 20th
Positive
Zacks Investment Research
1 month ago
New Strong Buy Stocks for January 20th
TV, ALLT, CMTG, PLBC and ARGX have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2025.
New Strong Buy Stocks for January 20th
Charts implemented using Lightweight Charts™